In a phase 3 trial of pimavanserin that came to a premature halt for efficacy, patients with dementia-related psychosis who continued the treatment had a lower risk for relapse than those who were ...

A 26-week, randomized, double-blind, placebo-controlled phase 2 study showed pimavanserin reduced negative schizophrenia symptoms in stable patients. Researchers noted that further study with ...

The atypical antipsychotic pimavanserin (Nuplazid) reduced the risk of dementia-related psychosis relapse, according to the phase III HARMONY trial. Following an open-label treatment phase to ...

On August 5, 2014, Acadia Pharmaceuticals (ACAD) reported financial results for the second quarter 2014 ended June 30, 2014. Revenues in the quarter totaled $28,000 compared to $451,000 for the ...

Pimavanserin doesn't cure ADP, it attempts to ameliorate the psychosis for the rest of the patient's life. Any pt with ADP has to dose with an antipsychotic the rest of their life.

A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis. The HARMONY ...

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events ...

In the 26-week phase II study, people on pimavanserin added to a main antipsychotic saw a significant improvement in the Negative Symptom Assessment-16 (NSA-16) total score (least squares mean -10 ...

Pimavanserin's potential sales may exceed a billion dollars. I argue that the -020 clinical trial design is excellent for what it is designed to prove or disprove.

Pimavanserin reduced psychosis at 6 weeks in patients with Alzheimer's disease compared with placebo. But at least one expert says the findings may simply be due to chance.

Pimavanserin has cleared another hurdle on the road to becoming the first antipsychotic approved for use in any neurologic disease. A Food and Drug Administration committee voted 12 to two that the ...

Pimavanserin works by blocking serotonin 5HT2A receptors, and doesn't interact with the dopamine receptors. It is licensed in the US to treat hallucinations and delusions in people with Parkinson ...